LentiGlobin BB305 Drug Product
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for LentiGlobin BB305 Drug Product, covering 2019-05-08 to 2023-06-18. Get the full timeline:
Most recent: Clinical Trial Update: A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype [Phase 3]